Aker BioMarine Future Growth

Future criteria checks 3/6

Aker BioMarine's revenue is forecast to decline at 5.3% per annum while its annual earnings are expected to grow at 97.6% per year. EPS is expected to grow by 97.4% per annum. Return on equity is forecast to be 8.5% in 3 years.

Key information

97.6%

Earnings growth rate

97.4%

EPS growth rate

Food earnings growth	10.2%
Revenue growth rate	-5.3%
Future return on equity	8.5%
Analyst coverage	Low
Last updated	22 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

MUN:1PG - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	282	22	23	33	2
12/31/2025	250	12	9	13	2
12/31/2024	264	1	-18	-3	2
9/30/2024	335	3	14	52	N/A
6/30/2024	338	-11	26	69	N/A
3/31/2024	336	-8	6	51	N/A
12/31/2023	335	-9	-2	47	N/A
9/30/2023	227	-15	-20	25	N/A
6/30/2023	242	0	-41	5	N/A
3/31/2023	268	14	-35	12	N/A
12/31/2022	277	10	-31	15	N/A
9/30/2022	274	1	-43	-2	N/A
6/30/2022	268	10	-27	9	N/A
3/31/2022	269	-8	-29	4	N/A
12/31/2021	262	-8	-78	3	N/A
9/30/2021	262	3	-85	-17	N/A
6/30/2021	270	-8	-139	-63	N/A
3/31/2021	268	-14	-134	-59	N/A
12/31/2020	289	-5	-75	-51	N/A
9/30/2020	285	-26	-65	-23	N/A
6/30/2020	284	-28	-12	19	N/A
3/31/2020	278	-18	-3	33	N/A
12/31/2019	246	-24	-115	12	N/A
12/31/2018	154	-1	-57	8	N/A
12/31/2017	126	-18	N/A	N/A	N/A
9/30/2017	123	-15	N/A	N/A	N/A
6/30/2017	122	-11	N/A	N/A	N/A
3/31/2017	119	-5	N/A	N/A	N/A
12/31/2016	117	-2	N/A	21	N/A
9/30/2016	111	-8	N/A	N/A	N/A
6/30/2016	110	0	N/A	N/A	N/A
3/31/2016	109	-3	N/A	N/A	N/A
12/31/2015	105	1	N/A	18	N/A
9/30/2015	105	-5	N/A	N/A	N/A
6/30/2015	103	-14	N/A	N/A	N/A
3/31/2015	111	-13	N/A	N/A	N/A
12/31/2014	112	-17	N/A	-11	N/A
9/30/2014	99	-34	N/A	N/A	N/A
6/30/2014	109	44	N/A	N/A	N/A
3/31/2014	106	43	N/A	N/A	N/A
12/31/2013	109	47	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1PG's forecast earnings growth (97.6% per year) is above the savings rate (1%).

Earnings vs Market: 1PG's earnings (97.6% per year) are forecast to grow faster than the German market (21.1% per year).

High Growth Earnings: 1PG's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1PG's revenue is expected to decline over the next 3 years (-5.3% per year).

High Growth Revenue: 1PG's revenue is forecast to decline over the next 3 years (-5.3% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 1PG's Return on Equity is forecast to be low in 3 years time (8.5%).

Aker BioMarine Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Aker Biomarine as Reiterates Earnings Guidance for the Full Year of 2022

Forecast breakeven date moved forward to 2022

Forecast breakeven pushed back to 2022

Forecast breakeven pushed back to 2022

Recent updates

Now 45% undervalued

Less than half of directors are independent

Aker BioMarine AS Announces Extraordinary Dividend, Payable on 30 September 2024

Second quarter 2024 earnings released: US$0.03 loss per share (vs US$0.005 profit in 2Q 2023)

Aker BioMarine AS Expects to Pay Extraordinary Dividend

Aker BioMarine Antarctic Holding II AS completed the acquisition of Feed Ingredients business of Aker BioMarine AS (OB:AKBM).

AIP, LLC and Aker Capital ASA agreed to acquire Feed Ingredients business from Aker BioMarine AS (OB:AKBM).

AIP, LLC and Aker Capital ASA agreed to acquire Feed Ingredients business from Aker BioMarine AS (OB:AKBM).

Less than half of directors are independent

Full year 2023 earnings released: US$0.10 loss per share (vs US$0.11 profit in FY 2022)

No independent directors

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.05 profit in 3Q 2022)

Aker BioMarine AS, Annual General Meeting, Apr 16, 2024

No independent directors

Aker BioMarine ASA Receives Approval for LYSOVETA as New Dietary Suppient in the US

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

No independent directors

Full year 2022 earnings released: EPS: US$0.11 (vs US$0.091 loss in FY 2021)

No independent directors

Chairman recently bought €495k worth of stock

Full year 2022 earnings released: EPS: US$0.11 (vs US$0.091 loss in FY 2021)

No independent directors

Aker BioMarine ASA Announces Ministry of Food and Drug Safety in South Korea Approves Superba Krill Oil

No independent directors

Third quarter 2022 earnings released: EPS: US$0.05 (vs US$0.15 in 3Q 2021)

No independent directors

Aker Biomarine as Reiterates Earnings Guidance for the Full Year of 2022

Aker BioMarine AS Appoints Mr. Øyvind Eriksen as an Observer to the Board on June 8, 2022

No independent directors

Aker Biomarine AS Announces Board Changes

Aker BioMarine AS, Annual General Meeting, Apr 20, 2022

Aker BioMarine AS, Annual General Meeting, Apr 20, 2022

Forecast breakeven date moved forward to 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

No independent directors

No independent directors

Forecast breakeven pushed back to 2022

Forecast breakeven pushed back to 2022

Forecast breakeven moved forward to 2021

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.08 loss in 1Q 2020)

Aker BioMarine AS Announces Executive Elections

Full year 2020 earnings released

Revenue misses expectations

Play Magnus Group and Aker Biomarine Signs A Four-Year Agreement for LYSOVETA

Aker BioMarine AS to Report Fiscal Year 2020 Results on Mar 05, 2021

Aker BioMarine AS Launches INVI, A Novel Protein for Human Consumption

Aker Biomarine Signs First Pharmaceutical Agreement for Development of Therapies Based on LYSOVETA

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies